The role of folate in the prevention of neural-tube defects

BY JOHN SCOTT¹, PEADAR KIRKE³, ANNE MOLLOY², LESLIE DALY⁴ AND DONALD WEIR²

Departments of ¹Biochemistry and ²Clinical Medicine, Trinity College, Dublin, Republic of Ireland, ³Health Research Board, Dublin, Republic of Ireland and ⁴Department of Public Health Medicine, University College, Dublin, Republic of Ireland

Between days 24 and 28 post-conception the neural tube closes to form the spinal cord and the cranium. Incomplete closure of the former causes spina bifida and of the latter, anencephaly, the two conditions being collectively called neural-tube defects (NTD; O'Rahilly & Muller, 1994). While there is clearly a genetic component to the aetiology of NTD the prevalence within any stable genetic pool varies significantly, indicating that other factors are involved. The other factor most commonly implicated is nutrition. Recently this area has advanced greatly with the now clear and universally accepted discovery that folate is this variable nutritional factor. As reviewed by Wald (1994), pteroylglutamic acid (folic acid) can prevent certainly over half, and in some studies all, NTD.

HOW DOES FOLATE PREVENT NTD?

The studies referred to previously were of two types and are summarized by Wald (1994) in a recent CIBA Symposium publication. Some eight prospective intervention trials have found that giving folic acid periconceptually to women dramatically reduced the prevalence of NTD. A different approach was used in some six studies that retrospectively examined the prevalence of NTD in women who happened to have been taking folic acid supplements compared with suitably matched controls not taking supplements. In all but one of these latter studies (Mills et al. 1989), there was a dramatic reduction in prevalence of NTD in the former group. In the intervention trials very large amounts of folic acid were used, from 400 µg to 4-0 mg daily. Similarly in the studies on the effect of folic acid supplements the amounts involved were 400 µg folic acid daily. The recommended daily allowance for folate in most countries is about 200 to 300 µg/d (Bailey, 1994). In addition the mean dietary intake of folate in women of child-bearing age is under 200 µg/d (Hoppner et al. 1977). Both these latter values are for food folate which is perhaps half as bioavailable as folic acid, the synthetic form used in the studies mentioned previously (Gregory et al. 1991). Thus, it is clear that ingestion of 400 µg folic acid/d represents a vast increase in the intake of folate over what is usually available. This finding, therefore, presents two possible mechanisms whereby folic acid prevents NTD. Folic acid could be correcting deficiency of folate in these women or it could be overcoming a metabolic block in folate metabolism.

NUTRITIONAL DEFICIENCY OR A METABOLIC BLOCK?

A way of resolving which of these two aetiologies was operative seemed to us to determine folate status of women who had had an affected pregnancy and compare them with suitably collected controls who had had a normal pregnancy. It was clearly
Table 1. Plasma folate, erythrocyte folate and plasma cobalamin levels in mothers of children with neural-tube defects (cases) and in controls

<table>
<thead>
<tr>
<th></th>
<th>Cases (n 81)</th>
<th>Controls (n 247)</th>
<th>Statistical significance of difference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma folate (μg/l)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>3.47</td>
<td>4.59</td>
<td>P=0.002</td>
</tr>
<tr>
<td>Range</td>
<td>0.71–20.78</td>
<td>0.52–22.08</td>
<td></td>
</tr>
<tr>
<td><strong>Erythrocyte folate (μg/l)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>269.0</td>
<td>338.0</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Range</td>
<td>38.8–715.3</td>
<td>79.7–1302.2</td>
<td></td>
</tr>
<tr>
<td><strong>Plasma cobalamin (ng/l)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>243.0</td>
<td>296.0</td>
<td>P=0.001</td>
</tr>
<tr>
<td>Range</td>
<td>102–759</td>
<td>88–757</td>
<td></td>
</tr>
</tbody>
</table>

necessary to measure status in the pregnancy where neural-tube defective embryo had been produced. A suitable time at which status might be determined would be the first booking clinic.

With the assistance of the three Dublin maternity hospitals we collected plasma samples and samples prepared for erythrocyte folate analysis from 56,049 women at such clinics over a 4-year period. This was a very representative population with about 70% of the pregnancies in these hospitals being involved. All samples were stored under identical conditions at −20°C. When pregnancy outcome became known it was possible to retrieve from this bank samples from eighty-one affected pregnancies (cases) and to select 247 normal pregnancies (controls) to cover the period of collection and storage. There was no selection bias between cases and controls nor was there any difference in their preparation or storage.

There are two methods of determining folate status. These are the estimation of (1) serum or plasma folate level and (2) erythrocyte folate level. The former fluctuates with recent dietary intake. Furthermore, values obtained at the first booking clinic, usually some 2 months into pregnancy, would have a doubtful relationship with what pertained at the closure of the neural tube. By contrast erythrocyte folates are made during the short period of erythrocyte maturation in the marrow, are a direct reflection of the plasma folate level at that time and do not change subsequently (Hoffbrand et al. 1966). They give, therefore, an average status over the 120 d life of the erythrocyte and when taken at the first booking clinic could be expected faithfully to reflect folate status over the previous 4 months. Since the presence or absence of an NTD is not known at the first booking clinic it was necessary to collect samples from all women and await the outcome of the pregnancy some months later.
only 8.6% had a plasma folate level below 1.5 µg/l (Fig. 1) and 14.3% had erythrocyte folate levels below 150 µg/l, the usual cut-off points for deficiency (Fig. 2). Only three cases had values where both indices were in the deficient range. This clearly indicates that the vast majority of women who go on to have an NTD-affected embryo in the same pregnancy are not folate deficient, and that the role of folic acid in prevention is that of overcoming a metabolic block in folate metabolism.
WHERE IS THE METABOLIC BLOCK?

There are about sixteen folate-dependent enzymes to choose from. However, we found that cobalamin status was an independent risk factor for NTD in our cases. As with plasma and erythrocyte folate, cobalamin levels were lower in cases than in controls (Table 1). With eight exceptions, the levels of cobalamin in the cases were in the normal range, i.e. above 150 µg/l (Fig. 3). However, logistic regression analysis showed plasma cobalamin status to predict risk independently of a woman’s plasma folate and erythrocyte folate status (Kirke et al. 1993). If plasma cobalamin levels were reflecting difference in dietary intake and were correlated with risk because they simply mirrored folate intake, they would be dependent risk factors, which they are not. In addition, there was no correlation between plasma folate and plasma cobalamin in cases ($r = 0.095$) or controls ($r = 0.049$; Fig. 4).

If the independent involvement of cobalamin in NTD can be confirmed by ourselves and others it would be significant in identifying the site of the metabolic block. Only one metabolic reaction is dependent on both folate and cobalamin, namely that catalysed by the enzyme methionine synthase ($EC 2.1.1.13$; Fig. 5). Our results suggest that direct or indirect malfunctioning of this enzyme is responsible for the majority of NTD.

CONCLUSIONS

The birth defects spina bifida and anencephaly collectively known as NTD are due, in the vast majority of cases, to a metabolic block in folate metabolism. This metabolic block can be overcome by the intake of high levels of folic acid periconceptually. The suggested involvement of cobalamin as a separate and independent risk factor for NTD indicates that the affected enzyme is methionine synthase, the only mammalian enzyme that uses both folate and cobalamin.
Fig. 4. The relationships between plasma cobalamin level and plasma folate level in (a) neural-tube defect cases and (b) controls. Cases: $r = 0.095$, $P = 0.60$ (not significant); controls: $r = 0.049$, $P = 0.55$ (not significant).

Fig. 5. The enzyme methionine synthase ($EC\ 2.1.1.13$) depends upon folate and cobalamin for its activity.
REFERENCES


